IGC Pharma, Inc.
IGC · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -41.8% | -0.6% | 28.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.8% | 47% | 46.7% | 40.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -891.1% | -537.8% | -381.2% | -669.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -953.4% | -487.5% | -362.7% | -711.7% |
| EPS Diluted | -0.02 | -0.019 | -0.016 | -0.024 |
| % Growth | -3.6% | -23.7% | 33.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |